GlassScriptPhysician profile
Robert J Terranova
NPI 1871538330
$9,314.60
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,975 · 2020: $2,033 · 2021: $2,651 · 2022: $1,693 · 2023: $839 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,894.10 | 2019-2023 | Mavenclad |
| Biogen, INC. | $881.72 | 2019-2023 | Vumerity, Tysabri |
| Ucb, INC. | $759.86 | 2019-2023 | Briviact |
| Novartis Pharmaceuticals Corporation | $575.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $338.91 | 2019-2021 | |
| Lilly USA, LLC | $332.87 | 2019-2023 | Emgality, Reyvow |
| Abbvie INC. | $307.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $305.40 | 2019-2023 | Austedo |
| Lundbeck LLC | $269.96 | 2020-2023 | Vyepti |
| Supernus Pharmaceuticals, INC. | $255.24 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $244.16 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $235.62 | 2019-2023 | Ultomiris |
| Celgene Corporation | $193.93 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.83 | 2020-2021 | |
| Genentech USA, INC. | $162.80 | 2019-2024 | Ocrevus |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Terranova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.